ReviewCirculating cardiovascular markers and mediators in acute illness: an update
Introduction
Cardiovascular alterations are common in the acutely ill and are either caused, at least in part, or compensated for by vascular and neurohumoral responses, resulting in endogenous release of a variety of compounds altering vascular tone and cardiac function (Fig. 1). Obviously, the most intensive response is found in patients with shock, either from septic or non-septic origin, so that, for instance, catecholamines are released in the circulation and at nerve endings, following sympathetic stimulation. Conversely, circulating vasoactive markers and mediators not only help to understand the pathophysiology of cardiovascular dysfunction and shock, but may also help to stage syndromes, to judge treatment effects and to predict outcome. In fact, patients may develop organ dysfunction in the course of critical illness, and circulating vasoactive factors may not only play a role but may also help to predict organ failures. Furthermore, understanding the role of these cardiovascular mediators may help in designing future therapeutic studies and inclusion criteria. This could be done through stratification on the basis of circulating cardiovascular markers that bear pathophysiologic and prognostic relevance.
We will collectively review the evidence in the literature of the marker and mediator role of a variety of endogenously released and circulating cardio- and vasoactive substances in the acutely ill. First, we describe the factors, followed by their pathophysiologic and diagnostic role in major conditions in the acutely ill. We will not extensively discuss the animal pathophysiology, nor the contribution of the contact system, complements components or arachidonic acid metabolites to the circulatory alterations of the acutely ill.
Section snippets
Nitric oxide end products: nitrate/nitrite
In healthy humans, endothelial, constitutive nitric oxide synthase (eNOS) is the only origin of nitric oxide (NO) and its metabolic end products nitrite and nitrate, which can be measured in blood with help of the classical Griess reaction by spectrophotometry, fluorometry, colorimetry, liquid chromatography or other techniques [1], [2], [3], [4], [5], [6]. NO released from the vessel wall is first converted to nitrite and subsequently within erythrocytes to nitrate, which is predominant in
Sympathoadrenergic response
Activation of the baroreceptor by hypotension increases sympathetic tone and eventual adrenal release of catecholamines, including norepinephrine and epinephrine, the classic stress hormones. The levels of these substances are elevated in plasma during pump failure or shock, particularly in non-survivors, as measured with help of high performance liquid chromatography, for instance [31], [45], [46].
Endothelin
While there are three forms of endothelin (1, 2 and 3) and proendothelins (big endothelins),
Markers of cardiac injury: troponin
Circulating cardiac isoforms of troponin I and T (cTnI, cTnT), cardiac-specific proteins involved in myosin crossbridging and myocardial contraction and assessed with help of radioimmunoassays, are sensitive and specific markers of myocardial injury [57], [58], [59], [60], [61], [62]. Hence, circulating levels constitute sensitive markers of damage of the myocardial contraction apparatus in coronary syndromes and they appear of prognostic significance, but also in sepsis, shock and allied
Acute coronary syndromes, myocardial infarction and CHF
The neurohumoral response to ventricular dilatation and a relatively low cardiac output in evolving myocardial infarction and CHF includes activation of the RAA system, the sympathetic nervous system, the endothelin system, and the ANP/BNP and l-arginine/NO systems, even before clinical symptoms develop [14], [45], [72]. Circulating (big) endothelin levels and precursors are elevated during CHF, for instance after myocardial infarction and during/after cardiac surgery [34], [43], [45], [73],
Conclusion
There are many markers of mediator actions on the vessel wall and the heart in acute illness. Elucidation of these factors has helped to understand the pathophysiology of cardiovascular dysfunction of the acutely ill. Aligning of hemodynamic abnormalities with patterns of circulating cardiovascular markers/mediators may help to stratify patients with cardiovascular dysfunction for inclusion in studies. This may help to assess the causes, response to therapy and prognosis of cardiovascular
References (128)
- et al.
Nitrite and nitrate analyses: a clinical biochemistry perspective
Clin. Biochem.
(1998) - et al.
Compartmentalized inducible nitric-oxide synthase activity in septic shock
Lancet
(2000) - et al.
Asymmetrical dimethylarginigne (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality
Clin. Nutr.
(2003) - et al.
Plasma concentrations of α-human atrial natriuretic polypeptide and cyclic GMP in patients with heart disease
Am. Heart J.
(1987) - et al.
Brain natriuretic peptide in the management of heart failure
Chest
(2004) - et al.
Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction
Am. Heart J.
(1998) - et al.
Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease
Am. Heart J.
(1998) - et al.
Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction
Lancet
(1993) - et al.
Detection of C-type natriuretic peptide in human circulation and marked increase of plasma CNP level in septic shock patients
Biochem. Biophys. Res. Commun.
(1994) - et al.
Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting
J. Am. Coll. Cardiol.
(2001)
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction
J. Am. Coll. Cardiol.
Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea
J. Am. Coll. Cardiol.
Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery
J. Am. Coll. Cardiol.
Regulation of production and secretion of adrenomedullin in the cardiovascular system
Regul. Pept.
Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems
Gastroenterology
Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
J. Am. Coll. Cardiol.
The endocrine response to critical illness
Med. Clin. North Am.
Acute coronary syndrome. Biochemical strategies in the troponin era
Chest
Troponin as a risk factor for mortality in critically ill patients without coronary syndrome
J. Am. Coll. Cardiol.
Common causes of troponin elevations in the absence of acute myocardial infarction. Incidence and clinical significance
Chest
Serum cardiac troponin T as a prognostic marker in early sepsis
Chest
Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema
Am. Heart J.
Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism
Chest
Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left ventricular dysfunction
Lancet
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
Lancet
Endothelin antagonists
Lancet
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the endothelinA receptor antagonist trial in heart failure (EARTH): randomised, double-blind, placebo-controlled trial
Lancet
Increased nitric oxide production in heart failure
Lancet
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
Lancet
Diagnostic values of B-type natriuretic peptide and chest radiographic findings in patients with acute dyspnea
Am. J. Med.
Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored empirical therapy
Am. Heart J.
A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study
J. Am. Coll. Cardiol.
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin–angiotensin–aldosterone system and natriuretic peptides in chronic heart failure
Am. J. Cardiol.
Endogenous nitric oxide and low vascular resistance after cardiopulmonary bypass
J. Cardiothor. Vasc. Anesth.
The bioactive peptide endothelin causes multiple biologic responses relevant to myocardial and vascular performance after cardiac surgery
J. Thorac. Cardiovasc. Surg.
Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism
Am. Heart J.
Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension
J. Am. Coll. Cardiol.
Primary pulmonary hypertension
Lancet
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension. A 1-year follow-up study
Chest
Cirulating endothelin and nitrate–nitrite relate to hemodynamic and metabolic variables in human septic shock
Shock
Indices of nitric oxide synthesis and outcome in critically ill patients
Anaesthesia
Indexes of NO bioavailability in human blood
NIPS
High and low response in relation to nitric oxide formation but not in lipid peroxidation in patients with sepsis
Crit. Care Med.
Metabolism and extraction of nitric oxide in humans. An experimental and clinical study
Circ. Res.
Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway
Arterioscler. Thromb. Vasc. Biol.
Alpha-atrial natriuretic peptide, cyclic guanosine monophosphate, and endothelin in plasma as markers of myocardial depression in human septic shock
Crit. Care Med.
Release of cyclic guanosine monophosphate evaluated as a diagnostic tool in cardiac diseases
Clin. Chem.
Measurement and significance of circulating natriuretic peptides in cardiovascular disease
Clin. Sci.
Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone
J. Clin. Endocrinol. Metab.
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
Lancet
Cited by (10)
CGMP level in idiopathic Parkinson's disease patients with and without cardiovascular disease - A pilot study
2011, Parkinsonism and Related DisordersCitation Excerpt :We were interested whether this finding was connected to the PD and the related treatment per se, or reflected the overall health status of the patients. Since it has been argued that serum cGMP can also be elevated due to cardiovascular diseases [10,11], we hypothesized that serum cGMP will be higher in PD patients with concurrent cardiovascular disease (CVD) than in those without CVD or in healthy controls. Moreover, as testosterone deficiency is considered a likely risk factor in both iPD and CVD [12–15], we hypothesized that the deficiency would be higher in CVD-burdened PD patients.
Usefulness of mid regional pro-atrial natriuretic peptide in the exacerbations of chronic obstructive pulmonary disease
2011, Clinica Chimica ActaCitation Excerpt :ANP is involved in a complex pathway that regulates vasomotor tone, systemic blood pressure and electrolyte homeostasis and has several physiological properties, ranging from blood pressure lowering properties to natriuretic and diuretic properties [37]. As ANP is a marker of renal and cardiovascular dysfunction, its levels are understandably increased in patients with these conditions [38]. Although further studies are required, serial measurements of MR-proANP might be useful for monitoring some specific COPD coexisting illnesses.
Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia
2007, Journal of InfectionCitation Excerpt :It is considered that BNP may be superior to ANP in monitoring heart failure. ANP is stored within granules and released upon acute stretch while BNP is not.8 The ANP prohormone in cardiac tissue is cleaved into two fragments, both of which enter the circulation.21
Hypotension, Hypovolemia, and Septic Shock
2007, Encyclopedia of StressClinical Implication of Blood Levels of B-Type Natriuretic Peptide in Pediatric Patients on Mechanical Circulatory Support
2006, Annals of Thoracic SurgeryA pilot study on the diagnostic accuracy of proadrenomedullin and proatrial natriuretic peptide in lower respiratory tract infections
2014, Open Respiratory Medicine Journal